Update with TapImmune, Inc. – Discusses Target Indications, Clinical Development, Milestones and Goals for 2016

LOS ANGELES, CA–(Marketwired – March 17, 2016) – StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Glynn Wilson, Ph.D., Chairman & CEO of TapImmune, Inc. (TPIV), an immuno-oncology company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, according to the Company’s website…

Details

TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016

TapImmune-Corporate-Presentation-2016 JACKSONVILLE, FLORIDA, March 14, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today the company’s Director, Dr. John Bonfiglio will present at the 28th Annual ROTH Conference on March 16, 2016 at…

Details

TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart – Next-Generation T-Cell Vaccine

Proprietary DNA Expression Vector Technology Developed at TapImmune’s Laboratories PolyStart to Move into Clinical Trials and Expand TapImmune‘s Development Pipeline TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today that it has received a Notice…

Details

TapImmune Inc. gets fast track status from FDA for study of its vaccine TPIV 200 to treat ovarian cancer

https://tapimmune.com/wp-content/uploads/2016/02/Jacksonville-Dot-Com.png TapImmune Inc., a Jacksonville-based immunotherapy company, has received fast track status from the U.S. Food & Drug Administration to study the use of its vaccine TPIV 200 to treat a certain form of ovarian cancer. by: Charlie Patton Immunotherapy is a type of cancer treatment designed to boost the body’s natural defenses in fighting…

Details

TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care

https://tapimmune.com/wp-content/uploads/2016/02/Donna-Foundation_295x166.jpg Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016 JACKSONVILLE, FLORIDA, February 10, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced the Company is a proud sponsor…

Details

TapImmune: Proud Supporter of World Cancer Day, February 4, 2016

https://tapimmune.com/wp-content/uploads/2016/02/World-Cancer-Day-300×150.jpg World Cancer Day is marked on February 4 to raise awareness of cancer and to encourage its prevention, detection, and treatment. World Cancer Day was founded by the Union for International Cancer Control to support the goals of the World Cancer Declaration, written in 2008. The primary goal of the World Cancer Day is…

Details

TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer. The…

Details

TapImmune Appoints Frederick G. Wasserman to its Board of Directors

TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G. Wasserman to its Board as an Independent Director. Frederick (Rick) is an accomplished Board Director with 35 years…

Details

TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016

https://tapimmune.com/wp-content/uploads/2016/01/Biotech-Showcase-2016.png JACKSONVILLE, FLORIDA, January 7 , 2015 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be a featured presenting company at Biotech Showcase 2016 to be held at the Parc 55, San Francisco Hilton,…

Details